Pune, India, Nov. 20, 2023 (GLOBE NEWSWIRE) — The global cardiac troponin market is projected to grow from USD 3.01 billion in 2023 to USD 5.17 billion by 2030, exhibiting a CAGR of 8.1% during the forecast period. The growing point-of-care test adoption in hospital emergency departments is expected to drive the cardiac troponin market growth during the projected period.
Fortune Business Insights™ mentioned this in a report titled, “Cardiac Troponin Market, 2023-2030.”
Request a Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-troponin-market-101234
Key Industry Development
May 2022 – Clinical Pathology Laboratories implements Roche’s generation 5 cardiac troponin T assay. The new assay is a highly sensitive cardiac troponin, which enables precise and more sensitive detection at low troponin concentrations.
Key Takeaways:
- Cardiac troponin is a diagnostic biomarker that detects cardiac muscle injury. Troponin I (cTnI) and troponin T (cTnT) are the cardiac regulatory proteins involved in controlling calcium-mediated interaction between actin and myosin.
- North America held the largest market share in 2022, generating a revenue of USD 1.14 billion.
- Rising cases of cardiovascular diseases is one of the main factors for the market growth.
- Market segments is anticipated to witness significant growth over the projected period.
List of Key Market Players Profiled in the Report:
“Companies leading the global Cardiac Troponin Market are F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Abbott (U.S.), Siemens Healthineers AG (Germany), Eurolyser Diagnostica GmbH (Germany), QuidelOrtho (Quidel Corporation) (U.S.), PerkinElmer Inc. (U.S.), Beckman Coulter, Inc. (Danaher) (U.S.), RESPONSE BIOMEDICAL (Canada), LifeSign LLC. (U.S.)”
Report Scope & Segmentation
| Report Coverage | Details |
| Forecast Period | 2023 to 2030 |
| Forecast Period 2023 to 2030 CAGR | 8.1% |
| 2030 Value Projection | USD 5.17 Billion |
| Base Year | 2022 |
| Market Size in 2023 | USD 3.01 Billion |
| Historical Data | 2019 to 2021 |
| No. of Pages | 150 |
| Segments covered | By Type, Setting, Indication, and Region |
Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/cardiac-troponin-market-101234
Segments:
Growing Importance of Troponin I Tests Propelled the Troponin I Segment Growth
Based on product, the market is divided into troponin T and troponin I. The troponin I segment accounted for the largest cardiac troponin market share in 2022. The growing importance of troponin I tests for predicting cardiovascular diseases and heart attack risks propelled segment growth.
Rising Adoption of POC Testing to Aid Point-of-Care (POC) Testing Segment Growth
By setting, the market is segmented into laboratory testing and point-of-care (POC) testing. The point-of-care (POC) segment growth is expected to experience highest growth during the forecast period. The growth is attributed to the rising adoption of point-of-care (POC) testing in new product launches, resource-limited settings, and rising regulatory approvals for POC testing products.
Rising Use of Cardiac Troponin to Detect Acute Coronary Syndrome Disease Propel Acute Coronary Syndrome Segment Growth
Based on indication, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and others. The acute coronary syndrome segment accounted for the largest market share in 2022 owing to the rising use of these tests to detect acute coronary syndrome disease globally.
Increased Hospitalizations During COVID-19 Pandemic to Aid Hospitals & Clinics Segment Growth
By end-user, the market is categorized into hospitals & clinics, diagnostic laboratories, and homecare settings & others. The hospitals & clinics segment held the largest market share during the projected period owing to the increased hospitalization and use of cardiac troponin tests during the pandemic to determine the myocardial infarction possibility in COVID-19 patients.
Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
By Type
- Troponin T
- Troponin I
By Setting
- Laboratory Testing
- Point-of-Care (POC) Testing
By Indication
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Others
By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Homecare Settings & Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy – https://www.fortunebusinessinsights.com/checkout-page/101234
Drivers & Restraints
Rising Key Players’ Focus on New Product Launches to Drive Market Growth
The key market players are increasing their focus on developing new and technologically advanced products, which is expected to drive market growth during the forecast period. The rising focus of key players to meet the unmet demands of the increasing patient population is estimated to aid market growth.
Regional Insights
North America to Dominate the Market Due to the Rising Prevalence of Cardiovascular Diseases
The North American market share accounted for USD 1.14 billion in 2022 and is anticipated to dominate the market during the projected period. The increasing product approvals by regulatory bodies, rising prevalence of cardiovascular diseases, and high availability of advanced products propel market growth in North America.
Asia Pacific is expected to grow at the highest CAGR during the forecast period due to the rising strategic initiatives by key players to expand their product portfolio.
Competitive Landscape
Rising Mergers and Acquisitions Between Major Players Augments Market Growth
The market comprises several major market players, including Abbott, Beckman Coulter, Inc., bioMérieux SA, PerkinElmer Inc., and others. The increasing number of mergers and acquisitions and new product launches between these key players is anticipated to drive market growth during the forecast period.
Speak to Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/cardiac-troponin-market-101234
FAQ’s
How big is the Cardiac Troponin Market?
Cardiac Troponin Market size was USD 2.79 billion in 2022. It is expected to reach USD 5.17 billion by 2030.
How fast is the Cardiac Troponin Market growing?
The Cardiac Troponin Market will exhibit a CAGR of 8.1% during the forecast period, 2023-2030
Related Reports:
Cardiac Pacemaker Market Growth, Industry Analysis, Demand and Forecast
Cardiac Rhythm Management (CRM) Devices Market Size, Share, Opportunities & Analysis
Cardiac Biomarkers Market Overview, Industry Share and Forecast
Biomarkers Market Demand, Size, Share and Forecast
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner – Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Attachment
- Cardiac Troponin Market
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
